Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Sonic Foundry completes $11.25M stock offer
4. Orion Energy completes $5M capital round
5. RedPrairie completes MARC acquisition
6. Metavante completes purchase of check processing firm
7. GE completes $1.2 billion acquisition
8. M & Is Metavante completes Brasfield Corp. acquisition
9. Metavante completes GHR Systems acquisition
10. Metavante completes TREEV acquisition
11. Johnson Controls completes sale of French unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible ... using single photon emission computed tomography (SPECT) according to researchers from Amen ... examined over 20,000 brain scans and is believed to be the largest brain imaging ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
(Date:7/1/2015)... ... , ... Apex Therapeutics announced today that company CEO, David Broecker provided a ... The presentation took place on Tuesday, June 16 and provided an update on the ... the treatment of pancreatic cancer. A copy of the company overview can be ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Health Services programs to control costs and improve member outcomes , ... Alere,s robust Integrated Health Management Solution(IHMS) platform fully ... , , , , ... completes IHMS installation to improve care and manage members, healthcare more consistently ...
... (Nasdaq: MNKD ), focused on discovering, developing ... that it will present at the 11th Annual Biotechnology ... February 9, 2009 at 2:15 PM (EST) at the ... In addition to this presentation, the Company will host ...
... Axentis Pharma AG is to present its,recent successes in ... lung disease at the 2nd Annual European Life Science ... three weeks after,the company was asked to present its ... USA. Part of the company,s ongoing success,story is a ...
Cached Biology Technology:Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 2Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 3Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 4MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 3
(Date:6/18/2015)... 2015 This report analyzes the worldwide markets ... Product Segments, which includes Immunoassay Analyzers and Reagents: Enzyme ... Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides ... , Japan , ... Latin America , and Rest of World. ...
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
(Date:6/17/2015)... , June 17, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Xiaomi, one of the ... ® ClearPad ® family of capacitive ... integrated circuits (DDICs) for its latest smartphones, the ... ClearPad for full in-cell display solutions and DDICs ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... a common parasitic infection can vary greatly from person to ... of three strains of the cat-borne parasite Toxoplasma gondii ... it invades. Past research suggests that the parasite, estimated ... exacerbate psychotic symptoms and schizophrenia in genetically predisposed people. ...
... relevant to the effects of a mother’s high-fat ... in her children. An animal study at ... high-fat, high-carbohydrate diet causes oxidative stress—an excess of ... obesity and diabetes. Feeding rats antioxidants before and ...
... researchers from universities across the United States will arrive ... talks with lawmakers and their staffs about how to ... fuel the pursuit for medical breakthroughs in a time ... students participating in Hill Day, a twice-annual event sponsored ...
Cached Biology News:Toxoplasmosis: The strain explains severity of infection 2Antioxidants in pregnancy prevent obesity in animal offspring 2Young scientists to make the case for research funding on Capitol Hill 2Young scientists to make the case for research funding on Capitol Hill 3Young scientists to make the case for research funding on Capitol Hill 4
... Leu-CMK FLISP Assay with SR-101 Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
... transmembrane potential is one of the ... induction of apoptosis. The MitoLight ... cation, termed as MitoLight, as a ... mitochondrial dye that stains mitochondria in ...
Biology Products: